160 related articles for article (PubMed ID: 37619523)
1. Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer.
Liu J; Liu Y; Yang C; Liu J; Hao J
Transl Oncol; 2023 Nov; 37():101762. PubMed ID: 37619523
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
3. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer.
Zhang W; Liu T; Jiang L; Chen J; Li Q; Wang J
Front Genet; 2022; 13():1001239. PubMed ID: 36425071
[No Abstract] [Full Text] [Related]
4. Novel immune-related gene signature for risk stratification and prognosis prediction in ovarian cancer.
Fei H; Han X; Wang Y; Li S
J Ovarian Res; 2023 Oct; 16(1):205. PubMed ID: 37858138
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
6. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
7. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
8. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer.
Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z
Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981
[TBL] [Abstract][Full Text] [Related]
9. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
[TBL] [Abstract][Full Text] [Related]
10. Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.
Li Y; Nie Y; Guo H; Guo H; Ha C; Li Y
Front Oncol; 2022; 12():847085. PubMed ID: 35372049
[TBL] [Abstract][Full Text] [Related]
11. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
[TBL] [Abstract][Full Text] [Related]
12. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
13. A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.
Chen S; Wu Y; Wang S; Wu J; Wu X; Zheng Z
J Ovarian Res; 2022 Mar; 15(1):39. PubMed ID: 35361267
[TBL] [Abstract][Full Text] [Related]
14. Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer.
Feng J; Yu Y; Yin W; Qian S
J Ovarian Res; 2023 Feb; 16(1):31. PubMed ID: 36739404
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients.
Zheng J; Guo J; Zhu L; Zhou Y; Tong J
J Ovarian Res; 2021 Sep; 14(1):124. PubMed ID: 34560889
[TBL] [Abstract][Full Text] [Related]
16. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
[TBL] [Abstract][Full Text] [Related]
17. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
[TBL] [Abstract][Full Text] [Related]
18. RB1 Is an Immune-Related Prognostic Biomarker for Ovarian Cancer.
Xie B; Tan G; Ren J; Lu W; Pervaz S; Ren X; Otoo AA; Tang J; Li F; Wang Y; Wang M
Front Oncol; 2022; 12():830908. PubMed ID: 35299734
[TBL] [Abstract][Full Text] [Related]
19. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.
Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J
Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a 9-gene signature for the prognosis of ovarian cancer by integrated bioinformatical analysis.
Chen S; Yang M; Yang H; Tang Q; Gu C; Wei W
Ann Transl Med; 2022 Oct; 10(19):1059. PubMed ID: 36330389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
